Last reviewed · How we verify
Loteprednol/tobramycin
Loteprednol reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis.
Loteprednol reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis. Used for Steroid-responsive inflammatory ocular conditions with bacterial infection or risk thereof, Post-operative ocular inflammation and infection.
At a glance
| Generic name | Loteprednol/tobramycin |
|---|---|
| Also known as | Zylet |
| Sponsor | Massachusetts Eye and Ear Infirmary |
| Drug class | Corticosteroid/aminoglycoside antibiotic combination |
| Target | Glucocorticoid receptor (loteprednol); bacterial 30S ribosome (tobramycin) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Loteprednol is a corticosteroid that suppresses inflammatory responses in the eye by binding glucocorticoid receptors and reducing production of inflammatory mediators. Tobramycin is an aminoglycoside antibiotic that inhibits bacterial 30S ribosomal subunit function, preventing protein synthesis and causing bactericidal activity. The combination addresses both inflammatory and infectious components of ocular disease.
Approved indications
- Steroid-responsive inflammatory ocular conditions with bacterial infection or risk thereof
- Post-operative ocular inflammation and infection
Common side effects
- Ocular irritation or discomfort
- Transient blurred vision
- Allergic conjunctivitis
- Secondary infection (if steroid-induced immunosuppression)
Key clinical trials
- Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial (PHASE1)
- A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis (PHASE4)
- Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis (PHASE4)
- Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis (PHASE4)
- Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis (PHASE3)
- Zylet vs TobraDex in Blepharokeratoconjunctivitis (PHASE4)
- Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex (PHASE4)
- Pediatric Zylet Safety and Efficacy Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loteprednol/tobramycin CI brief — competitive landscape report
- Loteprednol/tobramycin updates RSS · CI watch RSS
- Massachusetts Eye and Ear Infirmary portfolio CI